Matrix metalloproteinases (MMP) and plasminogen activator (PA)/plasmin-mediated proteolysis, especially at the cell surface, play important roles in matrix degeneration and smooth muscle cell migration, which largely contributes to vein graft failure. In this study, a novel hybrid protein was designed to inhibit both protease systems simultaneously. MMP and plasmin activity were inhibited at the cell surface by this hybrid protein, consisting of the receptor-binding amino-terminal fragment (ATF) of urokinase-type PA, linked to both the tissue inhibitor of metalloproteinases (TIMP-1) and bovine pancreas trypsin inhibitor (BPTI), a potent protease inhibitor. The effect of overexpression of this protein on vein graft disease was studied.
Introduction
Vein graft thickening of the arterialized vein after bypass surgery is an important cause of (late) bypass failure. 1 -3 Smooth muscle cell (SMC) migration and proliferation mostly contribute to the intimal hyperplasia, 4, 5 whereas the influx of inflammatory cells and lipid-loaded macrophages advance accelerated atherosclerosis. 6, 7 For SMC migration and invasion of inflammatory cells, a controlled breakdown of the extracellular matrix (ECM) is necessary. Matrix metalloproteinases (MMP) and proteases of the plasminogen activator (PA) system play key roles in the regulation of ECM degradation. 8 In this study, both the MMP and PA systems are targeted simultaneously in order to inhibit vein graft disease. For this purpose, a novel hybrid protein, TIMP-1.ATF.BPTI, was constructed.
On their own, the individual components of TIMP-1.ATF.BPTI are important regulators of the MMP and PA systems. Tissue inhibitors of metalloproteinases (TIMP) are the natural inhibitors of the MMP and regulate, together with inflammatory cells and cytokines, the activity and expression of MMP of which numerous are found in vascular cells. 9, 10 MMP are up-regulated in vein grafts after vascular injury and play a role in the degradation of (vascular) ECM proteins such as collagen and elastin. 11 -13 Overexpression of several TIMP decreased SMC migration and inhibited vein graft thickening in vitro as well as in vivo. 14 -19 In addition, TIMP and MMP have recently been reported also to exert non-protease-related functions. 20, 21 The second element of TIMP-1.ATF.BPTI, amino-terminal fragment (ATF), consists of the receptor-binding, non-proteolytic part of urokinase-type PA (u-PA) and contains the growth factor domain and the kringle domain of u-PA. Together with the serine protease domain, ATF forms the u-PA. u-PA, member of the serine protease family, can be recruited to the cell surface by its receptor, u-PAR, where u-PA converts the proenzyme plasminogen efficiently into plasmin. 22, 23 This results in direct pericellular proteolysis by ECM degradation and, indirectly, by activation of MMP proenzymes. 24 An increased expression of u-PA and its receptor is found in atherosclerotic plaques. 8, 25 ATF competes with u-PA for binding with u-PAR, resulting in hampered plasminogen activation. Previously, we reported that linking ATF to the third domain of TIMP-1.ATF.BPTI, bovine pancreas trypsin inhibitor (BPTI), also known as aprotinin and a very potent plasmin inhibitor, inhibited plasmin activity directly at the cell surface. 26 Adenoviral delivery of ATF.BPTI suppressed neointima formation in organ cultures of human saphenous veins as well as cuff-induced neointima in murine femoral arteries and balloon-injured rat carotid arteries in vivo.
27,28
Linking TIMP-1 to ATF enhanced the inhibitory effects of TIMP-1 on vein graft thickening in a human saphenous vein model. 29 The hybrid protein TIMP-1.ATF prevented local activation of plasminogen and inhibited MMP by competition of the ATF part with the binding of u-PA to its receptor and anchoring TIMP-1 directly to the cell surface.
In the present study, we describe the additive effect of linking the above-mentioned components to the newly constructed hybrid protein TIMP-1.ATF.BPTI ( Figure 1 ) in comparison with the individual domains. MMP and plasmin inhibition and receptor binding of the hybrid construct were analysed in vitro. Next, non-viral electroporation-mediated gene transfer of TIMP-1.ATF.BPTI plasmid was used to express TIMP-1.ATF.BPTI in cultured human vein segments to study the effect of TIMP-1.ATF.BPTI on neointima formation. In addition, the effect of TIMP-1.ATF.BPTI expression on vein graft thickening and remodelling in vivo was studied in hypercholesterolaemic APOE*3Leiden mice, which develop vein graft thickening with signs of accelerated atherosclerosis within 4 weeks after placing a venous interposition in the carotid artery.
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2. Methods
Plasmid construction
For the construction of TIMP-1.ATF.BPTI, the hybrid cDNAs ATF.BPTI and TIMP-1.ATF (previously constructed in our lab 26, 27, 29 ) were both digested at the ATF part, using DraIII and FseI restriction enzymes for the murine variant and SnaBI and FseI for the human form (Invitrogen, The Netherlands). Because the binding of u-PA, and also the ATF part, to its receptor is species-specific, 28, 32 two variants of TIMP-1.ATF.BPTI were constructed. One variant contains the human-specific ATF domains (hATF) and the other has three-point mutations in the human ATF domain, enabling binding of ATF to the murine u-PAR (mATF). 32 Next, DNA fragments were ligated with T4 DNA Ligase (Invitrogen), resulting in TIMP-1.ATF.BPTI. Subsequently, cDNA-encoding ATF, BPTI, TIMP-1, TIMP-1.ATF.BPTI, and luciferase as a control were subcloned into pcDNA3.1(+) expression vectors (Invitrogen).
Characterization of TIMP-1.ATF.BPTI
The MMP-inhibiting properties of the TIMP-1 moiety of TIMP-1.ATF.BPTI were determined as described before. 29, 33, 34 
Saphenous vein organ cultures
Human saphenous vein segments were obtained from patients who underwent varicose vein stripping, as approved by the Ethics review board of our hospital. The investigation conforms with the principles outlined in the Declaration of Helsinki. Segments of four patients were used and each segment was divided in small pieces (n ¼ 3 per group). After adding DEAE-dextran (1.5 mg/mL; Pharmacia Biotech AB, Sweden) to the electroporation solution and injection of plasmid DNA at multiple sites of the apical part of the venous segment, vein segments were 
Murine vein graft model
The animal welfare committee of the Netherlands Organization for Applied Scientific Research (TNO) approved the animal experiments. The investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). Male, 13-to 14-week-old APOE*3-Leiden mice on a C57BL/6 background were bred in our laboratory. After feeding with a western-type diet, these APOE*3Leiden mice develop hypercholesterolaemia and spontaneous atherosclerosis. 35, 36 For further details, see the Supplementary material online. Mice were allocated randomly to five groups (n ¼ 8 per group). During invasive procedures, animals were anaesthetized by i.p. injection of a mix of midazolam (5 mg/kg, Roche, The Netherlands), medetomidine (0.5 mg/kg, Orion, Finland), and fentanyl (0.05 mg/kg, Janssen-Cilag, The Netherlands). Non-viral gene transfer by intramuscular electroporation was performed using plasmids encoding TIMP-1, mATF, BPTI, TIMP-1. mATF.BPTI, and luciferase as a control, injected in both calf muscles, followed by eight electric pulses. 37 -39 The next day, vein graft surgery was performed as described previously 30 and in the Supplementary material online.
To determine circulating levels of TIMP-1.mATF.BPTI after electroporation with pTIMP-1.ATF.BPTI, serum samples were collected at 7 and 28 days. TIMP-1.mATF.BPTI concentrations were measured as described in the Supplementary material online previously using an u-PA ELISA 40 and are expressed as human urokinase equivalents.
Immunohistochemistry and quantification of vein graft thickening
Vein segments were cultured for 28 days as described previously, 41, 42 thereafter fixated in formaldehyde (4%), paraffin-embedded, and stained by haematoxylin-phloxine -saffron (HPS). For histological analysis of murine vein grafts, mice were sacrificed 28 days after surgery. Immunohistochemistry and morphometric analysis of human and murine vein segments was performed as described in the Supplementary material online. Vein graft thickening was defined as the area between the lumen and the adventitia and determined by subtracting the luminal area from the total vessel wall area, since in these murine venous segments, no clear boundary between intima and media can be detected due to the lack of internal elastic lamina. Therefore, the term vein graft thickening was used and not intimal hyperplasia or neointima.
Statistical analysis
Results are expressed as mean + standard error of the mean (SEM). Statistical significance was calculated in SPSS for Windows 15.0. Significance of differences between groups and their controls was determined using the Student's t-test or the one-way ANOVA with Dunnett's post hoc test when appropriate. P-values ,0.05 were considered statistically significant.
Results

Characterization of TIMP-1.ATF.BPTI
The MMP-inhibiting capacity of the TIMP-1 domain of TIMP-1.ATF.BPTI was assessed with an MMP-9 immunocapture activity assay. Diluted samples of conditioned medium of CHO cells expressing TIMP-1 and TIMP-1.ATF.BPTI inhibited MMP-9 activity. When compared with the control, MMP-9 activity was significantly reduced by 65.5 + 6.9% (TIMP-1) and 50.7 + 1.6% (TIMP-1.ATF.BPTI; Figure 2A ; *P , 0.05), whereas conditioned medium of BPTI-expressing CHO cells had no effect on MMP-9 activity. The plasmin inhibitory capacity of the BPTI domain of TIMP-1.ATF.BPTI was analysed in a plasmin inhibition assay. Plasmin activity was significantly inhibited by diluted samples of BPTI and TIMP-1.ATF.BPTI-containing CHO cell culture medium (BPTI: 39.2 + 1.7% and TIMP-1.ATF.BPTI: 36.1 + 0.1%; Figure 2B ; *P , 0.05). Conditioned medium of TIMP-1-expressing CHO cells did not influence plasmin activity when compared with the controls.
Cell surface binding of TIMP-1.ATF.BPTI to the u-PAR was demonstrated by fluorescence-activated cell sorter analysis of human u-PARexpressing murine LB6 cells (CL19) after incubation with conditioned medium of CHO cells expressing TIMP-1.hATF.BPTI. The heterogeneous u-PAR-expressing cell population shows that binding of the hybrid protein TIMP-1.hATF.BPTI to the u-PAR can be observed in the subpopulation of the cells that express u-PAR, whereas the u-PAR-negative cells were not able to bind TIMP-1.hATF.BPTI. , or luciferase as a control were incubated with active immunocaptured MMP-9. MMP-9 activity was measured after adding urokinase-specific chromogenic substrate S2444 using OD 405 measurement and is expressed in DOD 405nm /h 2 × 1000 + SEM; *P , 0.05. (B) Diluted samples of conditioned medium from CHO cells transfected with plasmids encoding TIMP-1, BPTI, TIMP-1.ATF.BPTI, or luciferase were analysed for plasmin inhibitory activity. Chromogenic substrate S2251 was added and plasmin activity was measured. Both BPTI-containing constructs decreased plasmin activity (expressed in DOD 405nm /h × 1000 + SEM; *P , 0.05).
TIMP-1.ATF.BPTI inhibits vein graft remodelling 
TIMP-1.ATF.BPTI inhibits vein graft remodelling
Using double-stainings for either TIMP-1 and u-PA/ATF or TIMP-1 and BPTI, the presence of the three components of the hybrid protein was demonstrated on the u-PAR-expressing subpopulation (see Figure 3 for details).
Effects of TIMP-1.ATF.BPTI on neointima formation in cultured human vein segments
To demonstrate the inhibitory effect of TIMP-1.hATF.BPTI on neointima formation in cultured human saphenous veins, vein segments were electroporated with a plasmid encoding the human variant of TIMP-1.ATF.BPTI and cultured for 4 weeks. The quality of gene transfer efficiency was assessed using electroporation-mediated transfection with pcDNA3.1-LacZ and demonstrated an efficient gene transfer of the segments, as indicated by the blue staining ( Figure 4A) . Furthermore, analysis of the luciferase activity after pLuciferase gene transfer revealed expression of 1.1×10 8 +
1.3×10
7 RLU/g tissue in the treated segments 4 days after electroporation, whereas no RLU could be detected in untreated vein segments (n ¼ 6). Both methods illustrate a qualitative gene transfer in the cultured saphenous vein segments. The expression of the pTIMP-1.hATF.BPTI construct after gene transfer was confirmed by the presence of TIMP-1.hATF.BPTI protein in the vessel wall after electroporation as assessed by immunohistochemistry using a polyclonal anti-trasylol antibody detecting the BPTI moiety. Figure 4B depicts that TIMP-1.hATF.BPTI is present throughout the whole vessel wall, but mainly concentrated in the neointima after 28 days. An explanation for this phenomenon may be that the receptor of u-PA (u-PAR) is concentrated in the neointima of the cultured vein segments. 27 TIMP-1.hATF.BPTI could not be detected in the control vein segments. After culturing for 4 weeks, a multilayer neointima was formed in control vein segments, whereas in TIMP-1.hATF.BPTI-treated sections, a marked reduction of neointima formation was observed ( Figure 4E and F ) . Vein graft thickening was inhibited in all vein segments, with a mean reduction in neointima formation of 36 + 14%, when compared with the paired controls (P ¼ 0.04; Figure 4G ).
TIMP-1.ATF.BPTI inhibits vein graft thickening in vivo
The inhibiting effect of TIMP-1.mATF.BPTI on vein graft disease in vivo was assessed using intramuscular electroporation to overexpress the murine variant of TIMP-1.mATF.BPTI in hypercholesterolaemic mice. Plasmids encoding for TIMP-1, mATF, BPTI, TIMP-1.mATF.BPTI, or luciferase as a control were injected in the calf muscles and electroporation was performed. The next day, a venous interposition was grafted into the carotid artery of these mice. During this study, animals were fed with a mild-western-type diet. Mean serum cholesterol levels and body weights were measured during the experiment. No significant differences were found between groups (mean cholesterol: 12.7 + 0.7 mmol/L; mean body weight: 27.2 + 0.2 g).
Blood samples were collected 1 week after intramuscular electroporation with pTIMP-1.mATF.BPTI and at sacrifice to determine circulating protein levels of TIMP-1.mATF.BPTI. A prolonged expression of TIMP-1.mATF.BPTI over the total experimental period was found as monitored by ELISA after electroporation of the calf muscles. At 1 week, serum levels were 131.8 + 33.9 ng/mL and declined to 81.5 + 19.2 ng/mL u-PA equivalents four weeks after electroporation (difference not significant), whereas no TIMP-1.ATF.BPTI was measured in the control groups.
Immunohistochemistry using a polyclonal anti-trasylol antibody visualized the presence of TIMP-1.mATF.BPTI throughout the whole vessel wall 4 weeks after electroporation with pTIMP-1.mATF.BPTI ( Figure 5D) . TIMP-1.mATF.BPTI could not be detected in the control vein segments.
Mice were sacrificed at 28 days and vein graft segments were analysed by quantitative morphometric software. As depicted in Figure 5A , overexpression of all concstructs led to a significant inhibition of vein graft thickening. Electroporation with the individual components of TIMP-1.mATF.BPTI resulted in a significant 36 -49% reduction when compared with the control (TIMP-1: 49 + 5%, mATF: 36 + 9%, and BPTI: 48 + 6%). The new hybrid construct pTIMP-1.mATF.BPTI displayed a significant stronger effect when compared with the individual components. Four weeks after electroporation and surgery, vein graft thickening was reduced by 67+4% in the pTIMP-1.mATF.BPTItreated mice when compared with the control (control: 0.62 + 0.09 mm 2 and TIMP-1.mATF.BPTI: 0.20 + 0.03 mm 2 ; P , 0.02). Also compared with electroporation with the individual components, electroporation with pTIMP-1.mATF.BPTI showed less vein graft thickening (P , 0.05). Furthermore, all constructs resulted in a reduction of outward remodelling (data not shown). As a consequence, the luminal area declined in the TIMP-1-and BPTI-treated mice when compared with the control (TIMP-1: 26 + 4% and BPTI: 19 + 5%). This adverse effect was not observed in vein segments grafted in pTIMP-1. mATF.BPTI electroporated mice, where the ratio of vein graft thickening to the luminal area was most beneficial ( Figure 5B) . Representative cross-sections of all groups are depicted Figure 5C . SMC content in the vein grafts was analysed to study the effect on cellular plaque composition after electroporation. Although an absolute reduction of SMCs could be observed at sacrifice, the effects on SMCs were similar in all groups. So, no significant relative reduction in SMC-positive content could be observed after treatment with either TIMP-1.ATF.BPTI or the other groups when compared with the control (Table 1) .
Discussion
In the present study, the effects of non-viral gene delivery of a novel hybrid protein, TIMP-1.ATF.BPTI, on vein graft thickening was analysed in two models for vein graft disease: in cultured human saphenous vein explants in vitro and in a murine in vivo vein graft model. This hybrid protein was designed in order to inhibit pericellular matrix metalloproteinases and plasmin activity simultaneously, which are both increased in diseased vein grafts. 8, 24, 43, 44 Electroporationmediated gene transfer of a plasmid vector encoding TIMP-1.ATF.BPTI, consisting of TIMP-1 (the natural TIMP) and BPTI, as a potent plasmin inhibitor, both linked to ATF (the amino-terminal receptor-binding domain of u-PA), reduced vein graft thickening in human and murine blood vessels. Previously, we demonstrated, using another method for gene transfer, i.e. adenoviral vectors, that an alternative hybrid protein, ATF.BPTI, reduced neointima formation efficiently in human saphenous veins in vitro as well as in murine femoral and rat carotid arteries in vivo. 7, 28 Inhibition of cell surface-bound plasmin activity by ATF.BPTI reduced SMC migration more potently than ATF or BPTI separately. 26 Along the same line, we designed another hybrid protein, TIMP-1.ATF, for inhibiting the MMP activity at the cell surface, and proved that it was more effective in preventing neointima formation in vein grafts in vitro when compared with the single domains. 29 Thus, since not only the PA systems but also the matrix metalloproteinase family members are thought to play a key role in neointima formation, 8 Results were determined by immunohistochemistry and values are expressed as immunopositive areas as a percentage of the total vein graft area in cross-sections (mean + SEM; differences not significant).
TIMP-1.ATF.BPTI inhibits vein graft remodelling MMP activity and plasmin activity at the cell surface by TIMP-1.ATF.BPTI may become a very effective way to reduce neointima formation and vein graft remodelling. As shown by our data, TIMP-1.ATF.BPTI was able to bind to human u-PAR-expressing murine LB6 cells 22 and is able to inhibit both MMP-9 and plasmin activity in vitro, confirming the functionality of the individual domains of the hybrid protein.
Next, the effect of TIMP-1.ATF.BPTI gene transfer on vein graft disease was assessed in two vein graft models. To avoid the inflammatory side effects of adenoviral gene transfer and to obtain a sustained expression of TIMP-1.ATF.BPTI, we used non-viral gene delivery by means of electroporation. In vivo, intramuscular electroporation is proven to be useful to deliver transgenes, resulting in prolonged circulating protein levels. 37, 46 Explantable saphenous veins can be modified in the operation theatre before grafting; therefore, they may be very suitable for extracorporeal gene therapy. Electroporation is an attractive method to deliver genes to the venous grafts, because, compared with viral gene delivery, electroporation has less undesired side effects, like inflammatory and immunological responses. 47, 48 However, in contrast to intramuscular electroporation in animal models, little is known about electroporation-mediated gene transfer to human veins. Therefore, we developed a new protocol, similar to the cuvette technique as described by Yamaoka et al. 49 Contrary to their findings, expression of TIMP-1.ATF.BPTI was seen throughout the whole vessel wall and not only in the adventitia. In human saphenous vein segments, electroporation of TIMP-1.hATF.BPTI resulted in a significant mean reduction of vein graft thickening of 36%. However, because of the difference in gene delivery techniques, this result is not comparable with the previously obtained effects by ATF.BPTI or TIMP-1.ATF. 27, 29 Nevertheless, these results are promising and since still reluctance exists to human viral gene delivery, this might be a substantial step for the application of gene therapy in the operation theatre. Intramuscular injection and electroporation of plasmids encoding for TIMP-1.ATF.BPTI was used to study the effect of the hybrid protein in a mouse model for vein graft disease. 30 In this model, caval veins of donor mice are placed as interposition in the common carotid artery of hypercholesterolaemic apolipoprotein E3-Leiden transgenic mice. Atherosclerotic lesions developed in these grafts proved several features as frequently observed in human diseased vessels, like SMCs accumulation in a 'cap-like' region, macrophages/foam cells accumulation beneath that layer, and the first signs of calcification and intraplaque haemorrhage. 31, 36 Circulating levels of murine TIMP-1.ATF.BPTI resulted in a profound attenuation of vein graft thickening, 4 weeks after electroporation and surgery. Also the individual components, TIMP-1, ATF, and BPTI inhibited vein graft thickening. However, this reduction was significantly less when compared with the effect of the hybrid protein (36-49 vs. 67%). Furthermore, electrodelivery of pTIMP-1.ATF.BPTI resulted in a more advantageous profile regarding to outward remodelling and preservation of luminal area. Unlike TIMP-1 or BPTI, the ATF part does not have an effect on lumen stenosis; however, it does affect vein graft thickening. This may indicate that not only the TIMP-1 and BPTI moieties are the efficacious domains as protease inhibitors, but also the binding of ATF to the receptor may have a specific effect on vascular remodelling, e.g. by inhibiting the enhanced plasminogen activation that is observed when u-PA binds to its receptor, u-PAR. 22 Finally, no significant reduction in relative SMC content and no negative effect of TIMP-1.ATF.BPTI on re-endothelialization was found (see Supplementary Material) was found, which is favourable to the stability of the lesion. 50 Also proliferation, as detected with a PCNA staining, was not significantly affected between all groups (see Supplementary Material). These observations support the hypothesis that TIMP-1.ATF.BPTI inhibits migration and not proliferation of SMCs.
In conclusion, our results show that cell surface-bound inhibition of the u-PA/plasmin and MMP system simultaneously with the hybrid protein TIMP-1.ATF.BPTI attenuated vein graft thickening in human saphenous veins ex vivo. Moreover, circulating serum levels of TIMP-1.ATF.BPTI lead to an efficient reduction of thickening of vein grafts in carotid arteries of hypercholesterolaemic APOE*3Leiden mice. This result was more potent in comparison with the three domains individually. Because extracorporeal electroporationmediated delivery of this novel hybrid protease inhibitor to the vein graft is feasible, this presents an attractive approach in the prevention of vein graft failure.
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